A5010067946- Antibiotics Pharmacokinetics and Efficacy
- Pharmaceutical studies and practices
- Pneumonia and Respiratory Infections
- HIV Research and Treatment
- Neonatal and Maternal Infections
- Bacterial Infections and Vaccines
- HIV/AIDS drug development and treatment
- Hepatitis C virus research
- Influenza Virus Research Studies
- HIV/AIDS Research and Interventions
- Antimicrobial Resistance in Staphylococcus
- Antifungal resistance and susceptibility
- Neonatal Respiratory Health Research
- Sepsis Diagnosis and Treatment
- Streptococcal Infections and Treatments
- Bacterial Identification and Susceptibility Testing
- Antibiotic Resistance in Bacteria
- SARS-CoV-2 and COVID-19 Research
- Fungal Infections and Studies
- Neonatal Health and Biochemistry
- HIV, Drug Use, Sexual Risk
- Hepatitis B Virus Studies
- Viral gastroenteritis research and epidemiology
- Respiratory viral infections research
- Computational Drug Discovery Methods
University of Tartu
2016-2025
Tartu University Hospital
1994-2017
Czech Academy of Sciences, Institute of Microbiology
2011-2015
Rega Institute for Medical Research
2015
KU Leuven
2015
Narodowy Instytut Zdrowia Publicznego PZH – Państwowy Instytut Badawczy
2014
University College London
2014
Bentham Science Publishers (China)
2013
Bentham Science Publishers (United Arab Emirates)
2013
Hospital de Dona Estefânia
2012
Treatments for invasive fungal infections remain unsatisfactory. We evaluated the efficacy, tolerability, and safety of voriconazole as salvage treatment 273 patients with refractory intolerant-to-treatment primary 28 which there is no approved therapy. Voriconazole was associated satisfactory global responses in 50% overall cohort; specifically, successful outcomes were observed 47% whose failed to respond previous antifungal therapy 68% have In this population at high risk failure,...
Objective. To describe the safety and efficacy of voriconazole in children treated within compassionate release program. Methods. Children received on a basis for treatment an invasive fungal infection if they were refractory to or intolerant conventional antifungal therapy. Voriconazole was administered as loading dose 6 mg/kg every 12 h iv Day 1 followed by 4 thereafter. When feasible route administration changed from oral (100 200 mg twice day patients weighing <40 ≥40 kg, respectively)....
The efficacy of voriconazole in 107 patients with scedosporiosis was analyzed. Principal infection sites were the lungs/sinuses (24%), central nervous system (CNS) (20%), and bone (18%), while 21% had disseminated infection. Solid organ transplantation (22%), hematological malignancy (21%), surgery/trauma (15%) predominant underlying conditions. A successful therapeutic response achieved 57% (median, 103 therapy days), > 98% those responding receiving or = 28 days therapy. Patients primary...
We conducted a multicenter study of the safety, tolerability, and plasma pharmacokinetics parenteral formulation voriconazole in immunocompromised pediatric patients (2 to 11 years old). Single doses 3 or 4 mg/kg body weight were administered six five children, respectively. In multiple-dose study, 28 received loading 6 every 12 h on day 1, followed by 2 8. Standard population pharmacokinetic approaches generalized additive modeling used construct structural covariate models this analysis....
Current in vitro and vivo data indicate that invasive aspergillosis due to Aspergillus terreus is resistant treatment with amphotericin B. Because little clinical are available guide therapy, we performed a retrospective cohort study of cases A. infections from 1997–2002 determine whether the use voriconazole, compared other antifungal therapies, led an improved patient outcome. We analyzed total 83 proven or probable infection (47% 53%, respectively). A 66.3% patients (55 83) died during...
We characterized voriconazole concentrations in the cerebrospinal fluid (CSF) of immunocompetent guinea pigs and patients with invasive fungal infections. In animals, after receipt oral doses 4 or 10 mg/kg every 8 h, mean ratios CSF to plasma total free drug concentration were 0.68 1.3, respectively. humans, 1-10 h voriconazole, ranged from 0.08 3.93 microg/mL, ratio 0.22 1.0 (median, 0.46).
Voriconazole is a potent triazole with broad-spectrum antifungal activity against clinically significant and emerging pathogens. The present population pharmacokinetic analysis evaluated voriconazole plasma concentration-time data from three studies of pediatric patients 2 to <12 years age, incorporating range single or multiple intravenous (i.v.) and/or oral (p.o.) doses. An appropriate model for this patient was created using the nonlinear mixed-effect modeling approach. final described...
The pharmacokinetics of voriconazole in children receiving 4 mg/kg intravenously (i.v.) demonstrate substantially lower plasma exposures (as defined by area under the concentration-time curve [AUC]) than those adults same therapeutic dosage. These differences between and limit accurate prediction pediatric exposure based on adult dosages. We therefore studied tolerability higher dosages an i.v.-to-oral regimen immunocompromised aged 2 to <12 years two dosage cohorts for prevention invasive...
With the increasing pace of global warming, it is important to understand role meteorological factors in influenza virus (IV) epidemics. In this study, we investigated impact temperature, UV index, humidity, wind speed, atmospheric pressure, and precipitation on IV activity Norway, Sweden, Finland, Estonia, Latvia Lithuania during 2010–2018. Both correlation machine learning analyses revealed that low temperature indexes were most predictive for epidemics Northern Europe. Our vitro...
BACKGROUND; Bone aspergillosis remains a rare but potentially devastating fungal disease. Although voriconazole is effective for invasive pulmonary aspergillosis, evidence of its efficacy located in bone limited.We report our experience with 4 cases aspergillosis. In addition, all probable and definite from the Pfizer clinical database were reviewed analyzed to determine safety treatment. Global response was evaluated at end therapy on basis composite assessment overall clinical,...
Human immunodeficiency virus type 1 (HIV-1) subtype may influence disease progression. We compared CD4 lymphocyte cell count levels at seroconversion, decline rates and viral load set point in individuals infected with different HIV-1 subtypes.We used data from the Concerted Action on SeroConversion to AIDS Death Europe (CASCADE) collaboration, restricted those since 1996, aged ≥15 years, applied mixed effects models for median regression (mean level 6-24 months seroconversion).The analysis...
Antibiotic dosing in neonates varies between countries and centres, suggesting suboptimal exposures for some neonates. We aimed to describe variations factors influencing the variability of frequently used antibiotics European NICUs help define strategies improvement. A sub-analysis Study Neonatal Exposure Excipients point prevalence study was undertaken. Demographic data receiving any antibiotic on day within one three two-week periods from January June 2012, dose, interval route...
Sepsis and bacterial meningitis are major causes of mortality morbidity in neonates infants. Meropenem, a broad-spectrum antibiotic, is not licensed for use infants below 3 months age sufficient information on its plasma CSF disposition dosing lacking. To determine pharmacokinetics meropenem young the link between clinical outcomes babies with late-onset sepsis (LOS). Data were collected two recently conducted studies, i.e. NeoMero-1 (neonatal LOS) NeoMero-2 meningitis). Optimally timed...
Objectives We aimed to describe administration of eight potentially harmful excipients interest (EOI)—parabens, polysorbate 80, propylene glycol, benzoates, saccharin sodium, sorbitol, ethanol and benzalkonium chloride—to hospitalised neonates in Europe identify risk factors for exposure. Methods All medicines administered during 1 day with individual prescription demographic data were registered a web-based point prevalence study. Excipients identified from the Summaries Product...
In an era of antibiotic resistance, medical students must be prepared to prescribe antibiotics responsibly. To assess self-reported preparedness among final-year at European universities, using a comprehensive set topics related prudent use. We conducted cross-sectional, multicentre, web-based survey. All medical-degree in their final year studies universities were eligible participate. A score was calculated for each student and mean scores compared school country levels. Comparisons made...